26 May 2013
Keywords: Transition Thera, Eli Lilly, Diabetes drug, TT-223, Fails to meet endpoints
Article | 20 September 2010
Canada’s Transition Therapeutics that a clinical study of gastrin analogue TT-223 in combination with an Eli Lilly (NYSE: ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 September 2010
21 September 2010
24 May 2013
© 2013 thepharmaletter.com